Navigation Links
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Date:1/15/2008

classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in a Phase 2 trial in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), is being evaluated in a Phase 1 trial in solid tumors in combination with trastuzumab and paclitaxel (Taxol(R)) and in a Phase 2 trial as monotherapy in HER2-positive metastatic breast cancer (intravenous) and in a Phase 1 trial in solid tumors (oral).

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercialization and other c
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
4. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
5. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
9. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
10. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
11. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry ... (Tray-style, Manifold, & Rotary) & Geography - Global ... defines and segments the lyophilization market on the ... analyses and projections of the market size of ...
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... 28 PRA International, a leading Clinical Research Organization, ... Association for the Study of Liver Diseases, The Liver ... in Boston, Massachusetts, USA. Representatives from PRA,s ... available at booth 300 to discuss our expertise in ...
... Inc. is pleased to introduce the GlideScope® Direct ... direct laryngoscopy. (Logo: http://photos.prnewswire.com/prnh/20061011/SFW044LOGO ... Made of stainless steel, the GlideScope Direct ... feel of a standard 3.5 size Macintosh blade. ...
Cached Medicine Technology:PRA International to Exhibit at Liver Diseases Conference 2Verathon® Introduces the GlideScope® Direct Intubation Trainer 2Verathon® Introduces the GlideScope® Direct Intubation Trainer 3
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... The Electronic Medical Records Systems ... medical records (EMR) and electronic health records (EHR) ... during the past five years and is expected ... years to 2019. The 2009 Health Information Technology ... and Medicaid incentives to encourage the widespread adoption ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
(Date:9/21/2014)... According to latest National Vital Statistics ... since 1966 (10.5 births per 1,000 women in 2013). Since ... risen steadily by 2 percent per year. The birth rate ... 50 and over) also rose, the first such increase since ... nine times as many first births to women aged 35 ...
Breaking Medicine News(10 mins):Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4
... News) -- The incidence of head and neck cancers related ... States, with the greatest increase among middle-aged white men, a ... risk factors for head and neck cancers, but the sexually ... well, according to researchers from the Louisiana State University Health ...
... Long-term follow-up of a phase II clinical trial ... non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic ... Annual Meeting 2012, held March 31 - April 4. ... to show unusually long survival in some patients," said ...
... Awakening from anesthesia is often associated with an ... restoration of awareness and orientation to one,s surroundings. ... consciousness emerges first. Using brain imaging techniques in ... Adjunct Professor Harry Scheinin, M.D. from the University ...
... (Boston) - Anurag Singh, PhD, assistant professor in ... Boston University School of Medicine has been invited ... for colon cancer at the American Association of ... Singh,s seminar, scheduled for Tuesday April 3rd, will ...
... , TUESDAY, April 3 (HealthDay News) -- Weight ... girls, self-esteem, according to a new study. "We found ... of obesity continued to see themselves as fat, despite changes ... associate professor of sociology at Purdue University in West Lafayette, ...
... Removing a lipoprotein receptor known as SR-BI may help ... presented at the American Association for Cancer Research Annual ... In vitro and mouse studies revealed that depletion of ... cell growth. SR-BI is a receptor for high-density ...
Cached Medicine News:Health News:HPV-Related Head, Neck Cancers on the Rise 2Health News:Scientists solving the mystery of human consciousness 2Health News:Scientists solving the mystery of human consciousness 3Health News:For Many Girls, Slimming Down Doesn't Help Self-Esteem 2Health News:Eliminating the 'good cholesterol' receptor may fight breast cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: